REFRENCES
Chihara, N., Aranami, T., Sato, W., Miyazaki, Y., Miyake, S., Okamoto, T., Ogawa, M., Toda, T., & Yamamura, T. (2011). Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proceedings of the National Academy of Sciences, 108(9), 3701–3706. https://doi.org/10.1073/pnas.1017385108
Correa-Díaz, E. P., Torres-Herrán, G. E., Miño Zambrano, J. E., Paredes-Gonzalez, V., & Caiza-Zambrano, F. J. (2021). Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 48, 102683. https://doi.org/10.1016/j.msard.2020.102683
Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., Green, A. J., Aktas, O., Hartung, H. P., Lublin, F. D., Drappa, J., Barron, G., Madani, S., Ratchford, J. N., She, D., . . . Katz, E. (2019). Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. The Lancet, 394(10206), 1352–1363. https://doi.org/10.1016/s0140-6736(19)31817-3
Cree, B. A., & Wingerchuk, D. M. (2005). Acute transverse myelitis: Is the “idiopathic” form vanishing? Neurology, 65(12), 1857–1858. https://doi.org/10.1212/01.wnl.0000194615.51750.f8
Ip, V. H., Lau, A. Y., Au, L. W., Fan, F. S., Chan, A. Y., Mok, V. C., & Wong, K. S. L. (2013). Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. Journal of the Neurological Sciences, 324(1–2), 38–39. https://doi.org/10.1016/j.jns.2012.09.024
Jacob, C. M. A., Pastorino, A. C., Fahl, K., Carneiro-Sampaio, M., & Monteiro, R. C. (2008). Autoimmunity in IgA Deficiency: Revisiting the Role of IgA as a Silent Housekeeper. Journal of Clinical Immunology, 28(S1), 56–61. https://doi.org/10.1007/s10875-007-9163-2
Jarius, S., & Wildemann, B. (2010). AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nature Reviews Neurology, 6(7), 383–392. https://doi.org/10.1038/nrneurol.2010.72
Kim, S. H., Huh, S. Y., Lee, S. J., Joung, A., & Kim, H. J. (2013). A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 70(9), 1110. https://doi.org/10.1001/jamaneurol.2013.3071
Yan, L., Kimko, H., Wang B., Cimbora, D., Katz, E., & Rees, W. A. (2021) Population pharmacokinetic modeling of inebilizumab in subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis or relapsing Multiple Sclerosis. Clin Pharmacokinet, (submitted)
The trials mention in the manuscript are registered with www.clintrials.gov.